• "Colonoscopy" is a procedure that allows a provider to examine the inner lining of the large intestine (rectum and colon) by using a thin, flexible tube called a colonoscope.
• "Double Contrast Barium Enema" is a form of contrast radiography in which x-rays of the colon and rectum are taken using barium contrast to visualize the internal structures more easily.
• "CT Colonography" or "Virtual Colonoscopy" is a procedure that uses special x-ray equipment to examine the large intestine for cancer or polyps.
• "Capsule Endoscopy" is a procedure where a small ingestible capsule is swallowed. This capsule has small cameras which take video as it moves through the digestive system to visualize the colon for detection of polyps.
"Incomplete Colonoscopy" refers to a situation when the colon cannot be fully evaluated for a number of reasons, such as patient discomfort, prior surgery, or suboptimal bowel preparation.
"Stool-Based Screening Tests" include the guaiac-based fecal occult blood test (gFOBT), fecal immunochemical test (FIT), and stool DNA testing (sDNA). While these tests typically cannot detect precancerous polyps, they may detect for other signs of cancer such as blood or cell debri in the stool.
Tests that fall within this definition include:
• "Guaiac-Based Fecal Occult Blood Test (gFOBT)" is a non-invasive screening tool that targets human red blood cell components in stool.
• "Fecal Immunochemical Test (FIT)" is a non-invasive screening tool that targets human red blood cell components in stool.
• "Stool DNA Test (sDNA)" is a non-invasive screening tool that targets both human red blood cell components and specific genetic alterations in stool.
Clinical Indications and Coverage
General Coverage Criteria: Average Risk Average risk includes persons who meet ALL of the following criteria:
• ONE of the following age groups:
○ Ages 50 to 75, for which regular screening indicated; or ○ Ages 76 to 85, for which screening is indicated based on individual's prior screening history and overall health status.
• No personal or family history of adenomatous polyps, colorectal cancer, familial adenomatous polyposis (FAP), or hereditary nonpolyposis colorectal cancer (HNPCC); and
• No personal history of inflammatory bowel disease such as Crohn's Disease or Ulcerative Colitis.
General Coverage Criteria: High Risk
People at increased or high risk of colorectal cancer should begin colorectal cancer screening before age 3 surveillance generally means a specific recommendation for colonoscopy. High risk includes persons who meet ONE of the following criteria:
• A personal history of colorectal cancer or adenomatous polyps; or
• A personal history of inflammatory bowel disease (ulcerative colitis or Crohn's disease); or ○ Guidelines recommend screening colonoscopy for these patients 8-10 years after diagnosis, with the interval for further surveillance guided by risk factors and findings at time of initial colonoscopy
• A family history of colorectal cancer or polyps; or ○ Persons with a first-degree relative in whom colorectal cancer developed before 60 years of age should undergo colonoscopy at 40 years of age or an age 10 years younger than the relative's age when cancer developed, whichever is earlier • African-Americans should begin their screening at age 45 due to a higher risk for colorectal cancer than other populations.
Covered Services & Criteria
The following tests can detect polyps (precancerous lesions) and cancer and are therefore indicated for average risk OR high risk patients: i.
Once every 10 years for average risk patients; or
ii. For high risk members, a screening interval appropriate for the individual's underlying high risk indication and associated degree of risk.
2.
A Sigmoidoscopy may be indicated as a preventive measure when ALL of the following are present:
a. 
Coverage Exclusions
Colorectal cancer screening is currently NOT recommended for average risk patients age 85 or older.
The application and clinical utility of the Capsule Endoscopies are considered experimental or investigational and are therefore not covered:
• Colon capsule endoscopy (e.g., PillCam COLON 2)
• Patency capsule (e.g., PillCam Patency System) Any colorectal cancer screening tests for which safety and efficacy has not been established and proven is considered experimental, investigational, or unproven, and is therefore not covered by Oscar. Noncovered screening tests include, but are not limited to, the following:
• Colon Cancer Gene Expression Assay Oncotype DX
• Colon Cancer Gene Expression Assay GeneFx Colon 
